All entries for: Biologic

June 29, 2026

BioCryst

Layoffs

Durham, NC

501-1,000 employees

“BioCryst is exiting internal discovery work and will close its Birmingham, Alabama site by the end of 2026. The company said it will now prioritize external innovation over its own discovery programs. A spokesperson declined to say how many jobs the shutdown will affect.

The spokesperson told BioSpace on June 29 that the company is committed to supporting affected employees through the transition, and that commercial and clinical programs continue as planned.

The site is BioCryst’s Discovery Center of Excellence. The move comes about a month after the company dropped avoralstat, its diabetic macular edema candidate in Phase 1b testing, to concentrate on its rare disease pipeline.”

Disease Area: Rare Disease

Drug Type: Biologic, Small Molecule

Source

June 29, 2026

Replimune Group, Inc.

Neutral Outlook

Woburn, MA

201-500 employees

We cannot be sure whether additional legislation related to the IRA will be issued or enacted, or what impact, if any, such changes will have on the profitability of any of our drug candidates, if approved for commercial use, in the future. There also may be future changes unrelated to the IRA that result in reductions in potential coverage and reimbursement levels for our product candidates, if approved and commercialized, and we cannot predict the scope of any future changes or the impact that those changes would have on our operations.

Disease Area: Oncology

Drug Type: Biologic

Source

June 23, 2026

Tourmaline Bio

Layoffs

New York, NY

1-50 employees

Tourmaline Bio said goodbye to 60 employees at its New York headquarters months after being swallowed by Novartis.

The workforce reduction stems from the closure of a Tourmaline site at 27 West 24th in New York, according to a Workers Adjustment and Retraining Notification (WARN) alert for the state. The layoffs took effect May 29, though the notice was only posted last week.

Novartis moved to acquire Tourmaline in September last year, putting around $1.4 billion on the line on a fully diluted basis, the pharma said at the time. The transaction closed in late October.

Novartis has conducted several rounds of layoffs this year, including one that takes effect in August and will leave 76 New Jersey workers jobless. The pharma also announced in May that it would shutter a Germany facility by the end of 2028, which will affect 220 jobs. Novartis ran two other cycles of terminations—one in March and another in April—which together affected more than 170 staff in New Jersey.

Disease Area: Cardiology, Immune Diseases, Multiple

Drug Type: Biologic

Source

June 12, 2026

Genentech

Layoffs

South San Francisco, CA

10,000+ employees

Genentech has made changes to its research and early development group (gRED) that include parting ways with a high-profile executive who had been with the company since 1997. The South San Franciso–based biotech confirmed to BioSpace the “targeted adjustments” and departure of Vishva Dixit, who most recently served as vice president and senior fellow, physiological chemistry, research biology.

The restructuring is intended to ensure the Roche subsidiary’s capabilities and investments align with its core therapeutic areas, advance its portfolio and deliver transformative medicines to patients faster, according to Genentech. A spokesperson declined to share specific information about the layoffs, including how many employees were affected.

Endpoints News reported that Genentech is closing infectious disease and physiological chemistry units while downsizing other teams. Also, in addition to Dixit, other key departures include Todd McDevitt, vice president and head of cell therapy, and Man-Wah Tan, a vice president and senior fellow of infectious diseases, the media outlet reported.

Disease Area: Dermatology, Immune Diseases, Infectious Diseases, Multiple, Oncology, Rare Diseases, Respiratory Diseases

Drug Type: Biologic, Small Molecule

Source

June 10, 2026

Fulcrum Therapeutics

Layoffs

Cambridge, MA

51-200 employees

Just days after announcing it was exploring strategic alternatives for the business after ending development of its lead asset, Fulcrum Therapeutics is cutting 85% of its workforce, according to an SEC filing. The Cambridge, Massachusetts–based biotech will lay off 48 of its 57 employees as part of a restructuring plan approved May 31 meant to significantly reduce operating expenses and preserve capital. Fulcrum informed staff on June 4.

The company announced June 1 it is discontinuing development of pociredir in sickle cell disease, as it no longer sees a viable regulatory path for the drug. Fulcrum noted that the FDA had recently raised concerns regarding pociredir’s benefit-risk profile in that indication.

The biotech expects to mostly complete its layoffs during the second quarter. Fulcrum estimated it will incur about $4.2 million in costs in connection with its restructuring plan, consisting mostly of severance, benefits and related expenses.

Disease Area: Hematology, Multiple, Rare Diseases

Drug Type: Biologic, Small Molecule

Source

June 2, 2026

Merck

Layoffs

Rahway, NJ

10,000+ employees

Merck is again sending employees packing in Rahway, New Jersey. The pharma is laying off 88 employees at its location there effective Sept. 4, according to a Worker Adjustment and Retraining Notification Act notice. Last year, Merck disclosed it was letting go of 262 employees in Rahway over two rounds of cuts, one of which took effect this year.

In August 2025, the pharma divulged it was laying off 58 people at that site on Nov. 14. The news came shortly after Merck confirmed that its $3 billion cost-cutting move could affect about 6,000 employees as part of a multiyear process. In November, the pharma disclosed it would let go of 204 staffers in Rahway from Feb. 20 through May 11.

In February 2026, Merck then disclosed in a WARN notice that it would lay off 154 employees in Durham, North Carolina, on May 1.

Disease Area: Cardiovascular, Infectious Diseases, Multiple, Oncology, Respiratory Diseases

Drug Type: Biologic, Small Molecule

Source

May 27, 2026

Johnson & Johnson

Layoffs

New Brunswick, NJ

10,000+ employees

New Jersey’s job market is taking another hit, this time from pharma giant Johnson & Johnson, which is parting ways with 56 employees in New Brunswick, according to a Worker Adjustment and Retraining Notification (WARN) Act posting for the state. The layoffs will take effect on August 21.

This is J&J’s first announced workforce reduction of this year, according to a tally by BioSpace. But the pharma has for years been constantly reshaping its business to accommodate the loss of exclusivity of its autoimmune disease powerhouse Stelara—a campaign that has involved cutting back investments in other parts of its business, while putting more money into higher-value areas like cancer.

Other Big Pharma players to recently slash their New Jersey headcounts include Novartis, Bristol Myers Squibb and Novo Nordisk.

Disease Area: Immune Diseases, Multiple, Neurological Diseases, Oncology

Drug Type: Biologic, Small Molecule

Source

May 22, 2026

Novartis

Layoffs

Basel, Baselstadt

10,000+ employees

Novartis is continuing to trim its workforce in the U.S., letting go of 76 employees in East Hanover, New Jersey, according to a Worker Adjustment and Retraining Notification (WARN) Act alert for the state. The layoffs will take effect on Aug. 21.

This will be the third time this year that Novartis downsized its New Jersey operations. The first batch of layoffs was announced in March, affecting 114 employees set to take effect from June 26 through Nov. 27. The second hit came a month later, with 60 jobs projected to be cut from July 24 through Nov. 20.

Novartis earlier this month also announced that it would close down a production site in Germany by the end of 2028, eliminating 220 jobs in the process.

Disease Area: Cardiovascular, Dermatology, Immune Diseases, Multiple

Drug Type: Biologic, Small Molecule

Source

May 22, 2026

AbbVie

Layoffs

North Chicago, IL

10,000+ employees

AbbVie’s operations in Irvine, California, will be 85 employees leaner after July 20, with layoffs projected to take place on that date, according to a Worker Adjustment and Retraining Notification (WARN) Act alert.

The pharma has over 40 open posts available in California, including data science and biologics product development listings. A recent BioSpace report found that AbbVie CEO Robert Michael saw a 76% pay bump, with his total compensation package reaching $32.5 million last year as compared to $18.5 million in 2024.

As per BioSpace’s tally, this is the first time AbbVie has announced layoffs this year.

Disease Area: Dermatology, Gastrointestinal, Multiple, Neurological Diseases, Oncology

Drug Type: Biologic, Small Molecule

Source

May 15, 2026

Novartis

Layoffs

Basel, Baselstadt

10,000+ employees

Novartis is letting go of “a select number” of employees within its biomedical research organization, a company spokesperson confirmed to BioSpace in an emailed statement.

“Novartis continually assesses opportunities to support our growth strategy as a focused innovative medicines company,” the statement read. “We regularly evaluate our organizational setup to ensure it remains aligned with evolving priorities.”

The cuts are the latest in a series of made or projected layoffs at Novartis this year that in total affect nearly 400 employees. Earlier this month, the Swiss pharma announced plans to shutter a production facility in Wehr, Germany, by the end of 2028. Novartis expects that closure will eliminate 220 jobs. In March and April, the pharma disclosed between two Worker Adjustment and Retraining Notification (WARN) Act notices that it will let go of 174 employees in East Hanover, New Jersey. Of those cuts, layoffs affecting 114 people are effective June 26 through Nov. 27, while those impacting 60 staffers run from July 24 through Nov. 20.

Disease Area: Cardiovascular, Dermatology, Immune Diseases, Multiple, Oncology

Drug Type: Biologic, Small Molecule

Source